BioCentury | Feb 13, 2020
Finance

Feb. 12 Financial Quick Takes: Trio of follow-ons; plus Teva, PentixaPharm, Inotrem

...the region, Truxima rituximab-abbs, which it said has attained a 12-15% market share. Teva launched Truxima...
BioCentury | Jan 25, 2020
Company News

Pfizer seeking to dent market share with trio of discounted biosimilars

...Inc. and Biogen Inc. (NASDAQ:BIIB), at a discount of 24%. While it will compete with Truxima...
BioCentury | Jul 24, 2019
Company News

July 23 Company Quick Takes: FDA approves Pfizer’s Rituxan biosimilar; plus Intra-Cellular, OTC Tamiflu, Cimzia and more

...the second biosimilar of Rituxan, an anti-CD20 mAb, the agency has approved. The first was Truxima...
BioCentury | Jul 19, 2019
Company News

July 19 Company Quick Takes: First biosimilars of Avastin, Herceptin launched; plus Gilenya, Celltrion-Nan Fung and Celgene

...rights to three of Celltrion's biosimilars: Remsima infliximab (CT-P13), a biosimilar of Remicade; Truxima rituximab (CT-P10...
...Interleukin 17A; PDE-4 - Phosphodiesterase-4; S1P - Sphingosine-1 phosphate BC Staff Blitzima, Ritemvia, Truxima, Tuxella, biosimilar rituximab-abbs (CT-P10) Gilenya...
BioCentury | Jan 12, 2019
Finance

We all fall down

...Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) FDA and the Australian Therapeutic Goods Administration approve Truxima...
BioCentury | Jan 5, 2019
Finance

Ready to launch

The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record year...
BioCentury | Dec 21, 2018
Clinical News

FDA approves Celltrion's Herceptin biosimilar

...HER2-positive breast cancer. In April, Celltrion received complete response letters from FDA for Herzuma and Truxima...
...the BLA for Herzuma in June, and in November FDA approved a resubmitted BLA for Truxima...
BioCentury | Dec 14, 2018
Company News

FDA approves Celltrion's Herceptin biosimilar

...HER2-positive breast cancer. In April, Celltrion received complete response letters from FDA for Herzuma and Truxima...
...the BLA for Herzuma in June, and in November FDA approved a resubmitted BLA for Truxima...
BioCentury | Nov 30, 2018
Clinical News

FDA approves first biosimilar for NHL

...agency said Truxima is the first biosimilar approved in the U.S. to treat non-Hodgkin lymphoma. Truxima...
...Rituximab Biosimilar" ). Teva has exclusive rights to commercialize Truxima in the U.S. and Canada. Truxima...
...Petach Tikva, Israel Product: Truxima rituximab-abbs Business: Cancer Elizabeth S. Eaton Blitzima, Ritemvia, Truxima, Tuxella, biosimilar rituximab (CT-P10) MabThera...
BioCentury | Nov 28, 2018
Company News

FDA approves first biosimilar for NHL

...agency said Truxima is the first biosimilar approved in the U.S. to treat non-Hodgkin lymphoma. Truxima...
...Rituximab Biosimilar" ). Teva has exclusive rights to commercialize Truxima in the U.S. and Canada. Truxima...
...FDA review with a PDUFA date in 3Q19. Elizabeth S. Eaton Blitzima, Ritemvia, Truxima, Tuxella, biosimilar rituximab (CT-P10) MabThera...
Items per page:
1 - 10 of 39